Perpetual Ltd Sells 3,508 Shares of Illumina, Inc. $ILMN

Key Points

• Perpetual Ltd reduced its holdings in Illumina, Inc. by 33.6% during the 2nd quarter, selling 3,508 shares and retaining a total of 6,917 shares valued at approximately $660,000.
• Institutional investors hold 89.42% of Illumina's stock, with several significant increases in stakes from firms like Rise Advisors LLC and Rakuten Securities Inc. in the last quarter.
• Illumina reported a quarterly earnings increase to $1.19 per share, surpassing analyst expectations, despite a 4.8% year-over-year revenue decline to $1.06 billion.

Perpetual Ltd decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 33.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,917 shares of the life sciences company's stock after selling 3,508 shares during the quarter. Perpetual Ltd's holdings in Illumina were worth $660,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Rise Advisors LLC increased its stake in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares during the period. Center for Financial Planning Inc. purchased a new position in Illumina in the 1st quarter valued at approximately $33,000. Fourth Dimension Wealth LLC bought a new stake in Illumina during the 4th quarter valued at $40,000. Finally, PFS Partners LLC lifted its position in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after acquiring an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the subject of several recent research reports. Robert W. Baird lifted their price target on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Royal Bank Of Canada set a $124.00 target price on Illumina in a research note on Tuesday, September 2nd. Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Barclays increased their price target on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Finally, Morgan Stanley raised their price objective on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of "Hold" and a consensus target price of $123.06.

Illumina Trading Down 0.3%

Shares of ILMN stock opened at $102.75 on Monday. The business has a 50-day moving average of $99.78 and a 200 day moving average of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The stock has a market capitalization of $15.79 billion, a PE ratio of 13.01, a P/E/G ratio of 2.31 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm posted $0.36 earnings per share. The business's quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.